Article
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Journal of hematology & oncology - 5 Sept 2022
Kunadt Desiree, Stasik Sebastian, Metzeler Klaus H, Röllig Christoph, Schliemann Christoph, Greif Philipp A, Spiekermann Karsten, Rothenberg-Thurley Maja, Krug Utz, Braess Jan, Krämer Alwin, Hochhaus Andreas, Scholl Sebastian, Hilgendorf Inken, Brümmendorf Tim H, Jost Edgar, Steffen Björn, Bug Gesine, Einsele Hermann, Görlich Dennis, Sauerland Cristina, Schäfer-Eckart Kerstin, Krause Stefan W, Hänel Mathias, Hanoun Maher, Kaufmann Martin, Wörmann Bernhard, Kramer Michael, Sockel Katja, Egger-Heidrich Katharina, Herold Tobias, Ehninger Gerhard, Burchert Andreas, Platzbecker Uwe, Berdel Wolfgang E, Müller-Tidow Carsten, Hiddemann Wolfgang, Serve Hubert, Stelljes Matthias, Baldus Claudia D, Neubauer Andreas, Schetelig Johannes, Thiede Christian, Bornhäuser Martin, Middeke Jan M, Stölzel Friedrich
Abstract excerpt
BACKGROUND: The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first complete remission (CR1) undergoing alloHCT or conventional chemo-consolidation and investigated outcome in respect to IDH1/2 mutational subgroups (IDH1 R132C, R132H and IDH2 R140Q, R172K)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.